PARP inhibitors for anticancer therapy

Biochemical Society Transactions

Volumn 42, Issue 1, 2014, Pages 82-88

  Curtin, Nicola ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Clinical trial; DNA repair; Poly(ADP ribose) polymerase (PARP); Synthetic lethality

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CELL DNA; DNA POLYMERASE; DNA TOPOISOMERASE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; TEMOZOLOMIDE; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DEAMINATION; DNA REPAIR; DNA RESPONSIVE ELEMENT; DNA STRAND BREAKAGE; EXCISION REPAIR; GENETIC MANIPULATION; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOSENSITIZATION; RECOMBINATION REPAIR; SUNGLE STRAND BREAK REPAIR; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; RECOMBINATIONAL DNA REPAIR;

EID: 84893262127     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130187     Document Type: Article

References (49)

1. Chambon, P., Weill, J.D. and Mandel, P. (1963) Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11, 39-43
2. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
3. Lindahl, T. (1993) Instability and decay of the primary structure of DNA. Nature 362, 709-715
4. Lindahl, T. and Wood, R.D. (1999) Quality control by DNA repair. Science 286, 1897-1905
5. Kennedy, R.D. and D'Andrea, A.D. (2006) DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J. Clin. Oncol. 24, 3799-3808
6. Schreiber, V., Dantzer, F., Ame, J.C. and de Murcia, G. (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528
7. El-Khamisy, S.F., Masutani, M., Suzuki, H. and Caldecott, K.W. (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31, 5526-5533
8. Durkacz, B.W., Omidiji, O., Gray, D.A. and Shall, S. (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283, 593-596
9. Ben-Hur, E., Chen, C.C. and Elkind, M.M. (1985) Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res. 45, 2123-2127
10. Ferraris, D.V. (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: from concept to clinic. J. Med. Chem. 53, 4561-4584
11. Javle, M. and Curtin, N.J. (2011) The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther. Adv. Med. Oncol. 3, 257-267
12. Ruf, A., de Murcia, G.M. and Schulz, G. (1998) Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 57, 3893-3900
13. Satoh, M.S. and Lindahl, T. (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 356-358
14. Kedar, P.S., Stefanick, D.F., Horton, J.K. and Wilson, S.H. (2012) Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol. Cancer Res. 10, 360-368
15. Murai, J., Huang, S.Y., Das, B.B., Renaud, A., Zhang, Y., Doroshow, J.H., Ji, J., Takeda, S. and Pommier, Y. (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588-5599
16. Jagtap, P. and Szabó, C. (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421-440
17. Mangerich, A. and Burkle, A. (2011) How to kill tumour cells with inhibitors of poly(ADP-ribose) polymerase. Int. J. Cancer 128, 251-265
18. Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann, S.H. and Poirier, G.G. (2010) PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 10, 293-301
19. Boulton, S., Pemberton, L.C., Porteous, J.K., Curtin, N.J., Griffin, R.J., Golding, B.T. and Durkacz, B.W. (1995) Potentiation of temozolomide cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer 72, 849-856
20. Bowman, K.J., Newell, D.R., Calvert, A.H. and Curtin, N.J. (2001) Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br. J. Cancer 84, 106-112
21. Delaney, C.A., Wang, L.Z., Kyle, S., Srinivasan, S., White, A.W., Calvert, A.H., Curtin, N.J., Durkacz, B.W., Hostomsky, Z., Maegley, K. et al. (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6, 2860-2867
22. Smith, L.M., Willmore, E., Austin, C.A. and Curtin, N.J. (2005) The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 11, 8449-8457
23. Banasik, M., Komura, H., Shimoyama, M. and Ueda, K. (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 267, 1569-1575
24. Calabrese, C.R., Almassy, R., Barton, S., Batey, M.A., Calvert, A.H., Canan-Koch, S., Durkacz, B.W., Hostomsky, Z., Kumpf, R.A., Kyle, S. et al. (2004) Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J. Natl. Cancer Inst. 96, 56-67
25. Evers, B., Drost, R., Schut, E., de Bruin, M., van der Burg, E., Derksen, P.W., Holstege, H., Liu, X., van Drunen, E., Beverloo, H.B. et al. (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925
26. Curtin, N. and Szabo, C. (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol. Aspects Med. 34, 1217-1256
27. Miknyoczki, S.J., Jones-Bolin, S., Pritchard, S., Hunter, K., Zhao, H., Wan, W., Ator, M., Bihovsky, R., Hudkins, R., Chatterjee, S. et al. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382
28. Thomas, H.D., Calabrese, C.R., Batey, M.A., Canan, S., Hostomsky, Z., Kyle, S., Maegley, K.A., Newell, D.R., Skalitzky, D., Wang, L.-Z. et al. (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 6, 945-956
29. Hartwell, L.H., Szankasi, P., Roberts, C.J., Murray, A.W. and Friend, S.H. (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064-1068
30. Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J. and Helleday, T. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917
31. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C. et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921
32. Schultz, N., Lopez, E., Saleh-Gohari, N. and Helleday, T. (2003) Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31, 4959-4964
33. McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z. et al. (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115
34. Drew, Y., Mulligan, E.A., Vong, W-T., Thomas, H.D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomsky, Z., Plummer, E.R. et al. (2011) Therapeutic potential of PARP inhibitor AG014699 in human cancer with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 103, 334-346
35. Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D. et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923
36. Plummer, R., Lorigan, P., Steven, N., Scott, L., Middleton, M.R., Wilson, R.H., Mulligan, E., Curtin, N., Wang, D., Dewji, R. et al. (2013) A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother. Pharmacol. 71, 1191-1199
37. Plummer, R. (2010) Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res. 16, 4527-4531
38. Bedikian, A.Y., Papadopoulos, N.E., Kim, K.B., Hwu, W.J., Homsi, J., Glass, M.R., Cain, S., Rudewicz, P., Vernillet, L. and Hwu, P. (2009) A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 27, 756-756
39. Khan, OA., Gore, M., Lorigan, P., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A.J., McGown, G., Thorncroft, M. et al. (2011) A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer 104, 750-755
40. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J.M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A.J. et al. (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626-5634
41. LoRusso, P., Ji, J.J., Li, J., Heilbrun, L.K., Shapiro, G., Sausville, E.A., Boerner, S.A., Smith, D.W., Pilat, M.J., Zhang, J. et al. (2011) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 29(Suppl.), 3000
42. Mehta, M.P., Curran, W.J., Wang, D., Wang, F., Kleinberg, L., Brade, A.M., Mostafa, N., Zhou, X., Qian, J., Leahy, T. et al. (2012) Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. J. Clin. Oncol. 30(Suppl.), 2013
43. Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M.J. et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134
44. Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C. et al. (2009) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519
45. Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251
46. Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K. et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244
47. Gelmon, K.A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B. et al. (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861
48. Ledermann, J.A., Harter, P., Gourley, C., Friedlander, M., Vergote, I.B., Rustin, G.J.S., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T. et al. (2011) Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J. Clin. Oncol. 29(Suppl.), 5003
49. Oza, A.M., Cibula, D., Oaknin, A., Poole, C.J., Mathijssen, R.H.J., Sonke, G.S., Colombo, N., Špacek, J., Vuylsteke, P., Hirte, H.A. et al. (2012) Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol. 30(Suppl.), 5001